Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic disea ...

Key Takeaways Eli Lilly is selling bonds to fund the acquisition of drug developer Morphic. The sale is reportedly worth $5 billion. The company's stock was upgraded by Deutsche Bank analysts following its quarterly results last week. Lilly shares jumped early in the day but closed in the red. Eli Lilly (LLY) shares finished Monday lower after a back-and-forth session in which an analyst upgrade sent them higher before news of $5 billion in bond sales pulled them into the red. Deutsche Bank analysts called ...

MONSEY, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Wohl & Fruchter LLP announces that on July 25, 2024, it filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Zappia v. Morphic Holding, Inc. et al., Case No. 3:24-cv-04486-JD, on behalf of a class ("Class") of individuals and entities holding the common stock of Morphic Holding, Inc. (Nasdaq: MORF) ("Morphic"), asserting claims under Sections 14(e) and 20(a) of the Securities Exchange Act of 1934, ...

Attorney advertising. Prior results do not guarantee similar outcomes. We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful. NEW YORK, July 28, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ: MORF) and Eli Lilly and ...

• successful enrollment of patients in, and the completion of, our clinical trials with favorable results; • receiving required regulatory authorizations for the development and approvals for the commercialization of our product candidates; • establishing and maintaining arrangements with third-party manufacturers; • obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates and their components; • enforcing and defending our intellectual property righ ...

NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Morphic Holding, Inc. (Nasdaq: MORF), relating to its proposed merger with Eli Lilly and Company. Under the terms of the agreement, Morphic Holding shareholders will receive $57.00 in cas ...

NEW YORK, July 9, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors ...

Eli Lilly (LLY) agreed to buy biopharmaceutical firm Morphic (MORF) at a significant premium, sending shares of Morphic skyrocketing Monday. The Waltham, Mass.-based company is also developing molecules intended to treat autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases, and cancer. Eli Lilly said it would buy Morphic for roughly $3.2 billion or $57 per share, a nearly 80% premium to Friday's closing price. Morphic is developing a treatment for inflammatory bowel disease. The deal is e ...

MONSEY, N.Y., July 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Morphic Holding, Inc. (Nasdaq: MORF) ("Morphic") to Eli Lilly and Company ("Eli Lilly") for $57.00 per share in cash in a tender offer. The sales price is below the price target for Morphic of at least five Wall Street analysts (source: TipRanks). If you remain a Morphic shareholder and question the fairness of the price, you may contact our firm at the following link to ...

-α4β7 Inhibition Rapidly Increases the Rolling Velocity and Flux of B Cells in Gut-associated Lymphoid Tissues- -Impact of Potent and Selective Small Molecule Inhibitor Comparable to Monoclonal Antibody Activity- -Preclinical Findings Presented at Digestive Disease Week 2024- WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced the presentatio ...